Hims & Hers Health Stock: Investor and Analyst Perspectives

Why This Matters: Understanding these trends can help investors assess the overall sentiment and potential future performance of HIMS stock. Insider selling might raise concerns, while institutional investment suggests confidence in the company's long-term prospects. Analyst ratings provide an external perspective on the stock's valuation and potential growth.

Institutional Investor Activity

Several institutional investors have recently adjusted their positions in Hims & Hers Health (HIMS). Dakota Wealth Management established a new stake, acquiring 7,100 shares valued at approximately $354,000 during the second quarter of 2025. Similarly, Occidental Asset Management LLC made a new investment, purchasing 6,112 shares worth around $305,000 in the same period.

However, not all institutional investors are increasing their positions. Abacus FCF Advisors LLC reduced its holdings by 52.6%, selling 62,147 shares. Despite the sale, Abacus FCF Advisors LLC still holds 55,943 shares of the company's stock, valued at $2,789,000.

Other firms like Geneos Wealth Management Inc., UMB Bank n.a., and Larson Financial Group LLC have also made changes to their positions, reflecting varied confidence levels among institutional investors.

Insider Trading

Recent insider trading activity reveals significant selling by top executives. CEO Andrew Dudum sold 660,000 shares at an average price of $50.58, totaling $33,382,800. Following this transaction, Dudum directly owns 2,214,769 shares valued at $112,023,016.02. CFO Oluyemi Okupe sold 145,000 shares at an average price of $55.35, amounting to $8,025,750. After the sale, Okupe holds 128,984 shares valued at approximately $7,139,264.40.

These insider sales represent a 22.96% and 52.92% decrease in Dudum and Okupe's positions, respectively. Such large sales by key executives can sometimes signal a lack of confidence in the company's near-term prospects, although there may be various personal financial reasons for these transactions.

Analyst Ratings and Price Targets

Analyst ratings on Hims & Hers Health are mixed. Citigroup reiterated a \"sell\" rating, while Canaccord Genuity reissued a \"buy\" rating with a $68.00 price objective. Truist Financial dropped their target price from $48.00 to $37.00, maintaining a \"hold\" rating. The consensus among analysts is a \"Reduce\" rating, with an average target price of $38.92.

Financial Performance

Hims & Hers Health reported its latest quarterly earnings on August 4th, 2025, announcing an EPS of $0.17, which missed the consensus estimate of $0.18 by $0.01. However, the company's revenue for the quarter was $544.83 million, up 72.6% compared to the same quarter last year. The company's return on equity is 26.26%, with a net margin of 9.63%.

Hims & Hers Health Profile

Hims & Hers Health, Inc. operates a telehealth consultation platform connecting consumers to healthcare professionals for mental health, sexual health, dermatology, and primary care. Founded in 2017 and headquartered in San Francisco, CA, the company aims to provide convenient and affordable access to healthcare services.

The consensus among analysts is a \"Reduce\" rating, with an average target price of $38.92.

Dakota Wealth Management and Occidental Asset Management are among the institutional investors that have recently invested in Hims & Hers Health.

The company's revenue increased by 72.6% compared to the same quarter last year.

Investors should consider the mixed signals from institutional investments, insider trading, and analyst ratings when evaluating Hims & Hers Health (HIMS).

Key Takeaways:

Do you think Hims & Hers Health will continue to attract institutional investment despite insider selling? Share your thoughts in the comments below!

Share this article with others who need to stay ahead of this trend!